Nadh Cytochrome B5 Reductase Deficiency Type Ii C2749562
A rare metabolic disorder affecting blood cells' ability to carry oxygen properly. Treatment involves managing symptoms and may include supportive therapies.
Key facts at a glance
- ICD-10
- G31.82
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Seizures
Cyanosis
(neurologic)Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Developmental delay
(neurologic)Microcephaly
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Methylene blue administration
Methylene blue serves as the primary treatment for methemoglobinemia in acute symptomatic presentations, rapidly reducing methemoglobin levels and improving oxygen delivery to tissues. Intravenous administration provides immediate correction of severe cyanosis and hypoxia.
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
Ascorbic acid supplementation
High-dose vitamin C provides a slower but safer alternative for reducing methemoglobin levels in chronic or mild cases. Oral administration supports gradual normalization of hemoglobin function.
Additional treatment options
Oxygen therapy
Supplemental oxygen administration improves tissue oxygenation during acute episodes while definitive treatment takes effect. Hyperbaric oxygen may be considered in refractory cases.
procedureMethemoglobin level monitoring
Regular pulse oximetry and laboratory measurement of methemoglobin levels guides treatment decisions and prevents complications. Continuous monitoring during acute episodes ensures timely intervention.
monitoringAvoidance of triggering agents
Patient education and strict avoidance of oxidizing drugs and environmental triggers prevents acute methemoglobinemia episodes. Medical alert identification ensures emergency providers avoid contraindicated medications.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Nadh Cytochrome B5 Reductase Deficiency Type Ii C2749562?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Nadh Cytochrome B5 Reductase Deficiency Type Ii C2749562. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy